AFT Pharmaceuticals - Near-term goals in sight with FY23 momentum
AFT Pharmaceuticals reported another strong fiscal year, capping off three consecutive years of double-digit top-line growth. FY23 revenues of...
215 Views
AFT Pharmaceuticals - Maxigesic IV closer to FDA approval
AFT Pharmaceuticals has announced that the US FDA has allocated a Prescription Drug User Fee Act (PDUFA) date for Maxigesic IV, an intravenous form...
150 Views
AFT Pharmaceuticals - Maxigesic international momentum continues
AFT Pharmaceuticals (AFT) has announced that it has signed three additional licensing agreements for Maxigesic IV – with Labatec in Switzerland and...
211 Views
AFT Pharmaceuticals - Big win with Maxigesic Rapid’s FDA nod
AFT Pharmaceuticals (AFT) has announced it has received FDA approval for Maxigesic Rapid tablets, a quick-release version of its flagship Maxigesic...
161 Views
AFT Pharmaceuticals - Portfolio expansion with new in-licensing deal
AFT Pharmaceuticals continues to strengthen its R&D pipeline with the announced in-licensing agreement with Latitude Pharmaceuticals (a...
247 Views